## 1 Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-

# 2 CoV-2 mRNA vaccination

- 3 Alexandra Tauzin<sup>1,2</sup>, Mehdi Benlarbi<sup>1,2</sup>, Halima Medjahed<sup>1</sup>, Yves Grégoire<sup>3</sup>, Josée
- 4 Perreault<sup>3</sup>, Gabrielle Gendron-Lepage<sup>1</sup>, Laurie Gokool<sup>1</sup>, Chantal Morisseau<sup>1</sup>, Pascale
- 5 Arlotto<sup>1</sup>, Cécile Tremblay<sup>1</sup>, Daniel E. Kaufmann<sup>1,4,5</sup>, Valérie-Martel-Laferrière<sup>1,2</sup>, Inès
- 6 Levade<sup>6</sup>, Marceline Côté<sup>7</sup>, Gaston de Serres<sup>8</sup>, Renée Bazin<sup>3</sup>, and Andrés Finzi<sup>1,2,#</sup>
- 7
- <sup>8</sup> <sup>1</sup>Centre de Recherche du CHUM, Montreal, QC, Canada
- 9 <sup>2</sup>Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada
- 10 <sup>3</sup>Héma-Québec, Affaires Médicales et Innovation, Quebec, QC, Canada
- 11 <sup>4</sup>Département de Médecine, Université de Montréal, Montreal, QC, Canada
- 12 <sup>5</sup>Division of Infectious Diseases, Department of Medicine, University Hospital of Lausanne and University of
- 13 Lausanne, Lausanne, Switzerland
- 14 <sup>6</sup>Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne de-
- 15 Bellevue, QC, Canada.
- <sup>7</sup>Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity, and
- 17 Inflammation, University of Ottawa, Ottawa, ON, Canada
- 18 <sup>8</sup>Institut National de Santé Publique du Québec, Quebec, QC, Canada
- 19
- 20 <sup>#</sup> Correspondance: Andrés Finzi, <u>andres.finzi@umontreal.ca</u>

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 2 of 19

#### 21 Abstract

22

23 The Omicron BQ.1.1 variant is now the major SARS-CoV-2 circulating strain in many 24 countries. Because of the many mutations present in its Spike glycoprotein, this variant is 25 resistant to humoral responses elicited by monovalent mRNA vaccines. With the goal to 26 improve immune responses against Omicron subvariants, bivalent mRNA vaccines have 27 recently been approved in several countries. In this study, we measure the capacity of plasma 28 from vaccinated individuals, before and after a fourth dose of mono- or bivalent mRNA 29 vaccine, to recognize and neutralize the ancestral (D614G) and the BQ.1.1 Spikes. Before 30 and after the fourth dose, we observe a significantly better recognition and neutralization of 31 the ancestral Spike. We also observe that fourth-dose vaccinated individuals who have been 32 recently infected recognize and neutralize better the BQ.1.1 Spike, independently of the 33 mRNA vaccine used, than donors who have never been infected or have an older infection. 34 Our study supports that hybrid immunity, generated by vaccination and a recent infection, 35 induces higher humoral responses than vaccination alone, independently of the mRNA 36 vaccine used.

37

38 Keywords: COVID-19, SARS-CoV-2, mRNA bivalent vaccine, Hybrid immunity, Humoral 39 responses, BQ.1.1

#### 40 Introduction

41 The Omicron BQ.1.1 variant is a sublineage of the BA.5 variant that spreads very rapidly 42 and is now the major circulating lineage in several countries [1,2]. Recent studies have shown 43 that original SARS-CoV-2 mRNA vaccines, based on the ancestral Wuhan strain Spike (S), 44 lead to poor humoral responses against several Omicron subvariants, including the BQ.1.1 45 variant [3–5]. With the goal to improve immune responses against these subvariants, 46 Moderna and Pfizer bivalent vaccines have recently been approved by health authorities in 47 many countries [6–8]. These updated versions of the vaccines are composed of mRNA coding 48 for the expression of both the ancestral and an Omicron subvariant S [9,10]. However, the 49 continued evolution of SARS-CoV-2 has resulted in the emergence of multiple Omicron sub-50 lineages showing signs of convergent evolution by the acquisition of the same immune 51 escape mutation in the RBD region of the Spike protein. Notably, all five recent convergent 52 mutations are present in BQ. 1.1: R346T, K444T, L452R, N460K, or F486V [3]. Because of 53 these newly acquired mutations, the benefits of bivalent compared to monovalent vaccines 54 against this lineage remain to be established.

55 It is well accepted now that hybrid immunity leads to better immune responses and 56 protection from severe outcomes than vaccination alone [11-17]. Because the original 57 mRNA vaccines poorly prevent viral transmission, an important part of the vaccinated 58 population have been recently infected by Omicron subvariants, leading to improved immune 59 responses in these individuals compared to SARS-CoV-2 naïve individuals who have just 60 been vaccinated.

61 In this study, we evaluated the capacity of plasma antibodies to recognize and neutralize 62 the original D614G and the Omicron BQ.1.1 subvariant S four weeks (W4-Va3) and four 63 months (M4-Va3) after the third dose and four weeks after the fourth dose (W4-Va4) of 64 mRNA vaccines (Figure 1A). These participants mainly received as their first three doses of 65 vaccine the Pfizer monovalent vaccine, and as the fourth dose either the Pfizer or Moderna monovalent or Pfizer (BA.4/5) or Moderna (BA.1) bivalent vaccines. We also measured the 66 67 anti-nucleocapsid (N) level to determine if the donors had recent breakthrough infection

4 of 19

(BTI), i.e., they have been infected between their third and fourth doses of vaccine by a
Omicron sublineage. Basic demographic characteristics of the cohort are summarized in
Table 1.

71

## 72 Materials and Methods

### 73 Ethics statement

The study was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. The protocol was approved by the Ethics Committee of CHUM (19.381, approved on February 28, 2022) and Héma-Québec (2022-016, approved on October 7, 2022).

## 78 Human subjects

79 The study was conducted in 63 individuals (25 males and 38 females; age range: 24-84 80 years). 20 of these individuals had recent breakthrough infection with an Omicron sublineage (9 males and 11 females; age range: 24-67 years), i.e. as determined by the increase in anti-81 82 N levels between W4-Va3 and M4-Va3 or between M4-Va3 and W4-Va4 using a recently 83 described analytical approach [18] (Figure S1). For the other donors (16 males and 27 84 females; age range: 31-84 years), we did not observe a significant increase of the anti-N 85 levels, although some of them have a history of infection. No other specific criteria such as 86 number of patients (sample size), sex, clinical or demographic were used for inclusion.

### 87 Plasma samples and antibodies

88 Plasma samples were either recovered from whole blood or directly obtained from the 89 PlasCov biobank [19], heat-inactivated for 1 hour at 56°C and stored at -80°C until use in 90 subsequent experiments. Pre-pandemic plasma samples were used as negative controls in 91 cytometry assays (data not shown). The conformationally independent S2-specific 92 monoclonal antibody CV3-25 was used as a positive control and to normalize Spike 93 expression in flow cytometry assays, as described [4,20–23]. Alexa Fluor-647-conjugated 94 goat anti-human antibodies (Abs) able to detect all Ig isotypes (anti-human IgM+IgG+IgA; 95 Jackson ImmunoResearch Laboratories, Cat # 109-605-064) were used as secondary Abs to 96 detect plasma binding in flow cytometry experiments.

### 97 Plasmids

5 of 19

The plasmids encoding the SARS-CoV-2 D614G and BQ.1.1 Spike variants were
previously described [4]. The pNL4.3 R-E-Luc plasmid was obtained from the NIH AIDS
Reagent Program (Cat# 3418). The pIRES2-EGFP expressing plasmid was purchased from

101 Clontech (Cat# 6029-1).

102 Cell lines

103 293T human embryonic kidney cells (obtained from ATCC, Cat# CRL-3216) were 104 maintained at 37°C under 5% CO<sub>2</sub> in Dulbecco's modified Eagle's medium (DMEM) 105 (Wisent) containing 5% fetal bovine serum (FBS) (VWR) and 100  $\mu$ g/ml of penicillin-106 streptomycin (Wisent). 293T-ACE2 cell line was previously reported [24].

# 107 Enzyme-linked immunosorbent assay (ELISA)

All samples were tested for anti-N total immunoglobulin levels using an in-house antiN ELISA. The assay protocol is similar to the anti-SARS-CoV-2 RBD ELISA previously
developed by our group [25], except that recombinant N (Centre National en Électrochimie
et en Technologies Environnementales Inc., Shawinigan, Canada) was used (0.25 μg/ml) in

112 lieu of the RBD antigen ( $2.5 \mu g/ml$ ).

# 113 Cell surface staining and flow cytometry analysis

114 293T were transfected with full-length SARS-CoV-2 Spikes and a green fluorescent 115 protein (GFP) expressor (pIRES2-eGFP) using the calcium-phosphate method. Two days 116 post-transfection, Spike-expressing 293T cells were stained with the CV3-25 Ab (5 µg/mL) 117 as control or plasma (1:250 dilution) for 45 min at 37°C. AlexaFluor-647-conjugated goat 118 anti-human IgM+IgG+IgA (1/800 dilution) were used as secondary Abs. The percentage of 119 Spike-expressing cells (GFP + cells) was determined by gating the living cell population 120 based on viability dye staining (Aqua Vivid, Invitrogen). Samples were acquired on a 121 LSRFortessa cytometer (BD Biosciences), and data analysis was performed using FlowJo 122 v10.7.1 (Tree Star). The conformationally-independent anti-S2 antibody CV3-25, effective 123 against all Spike variants, was used to normalize Spike expression, as reported [4,20,22,23]. 124 The Median Fluorescence intensities (MFI) obtained with plasma were normalized to the 125 MFI obtained with CV3-25 and presented as percentage of CV3-25 binding.

### 126 Virus neutralization assay

127 293T cells were transfected with the lentiviral vector pNL4.3 R-E- Luc and a plasmid

128 encoding the D614G or the BQ.1.1 S glycoprotein at a ratio of 10:1 to produce SARS-CoV-

6 of 19

129 2 pseudoviruses. Two days post-transfection, cell supernatants were harvested and stored at -80°C until use. For the neutralization assay, 293T-ACE2 target cells were seeded at a 130 131 density of  $1 \times 10^4$  cells/well in 96-well luminometer-compatible tissue culture plates 132 (PerkinElmer) 24h before infection. Pseudoviral particles were incubated with several plasma 133 dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for 1h at 37°C and were then added to the 134 target cells followed by incubation for 48h at 37°C. Cells were lysed by the addition of 30 µL 135 of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942 TriStar 136 luminometer (Berthold Technologies) was used to measure the luciferase activity of each 137 well after the addition of 100 µL of luciferin buffer (15mM MgSO<sub>4</sub>, 15mM KH<sub>2</sub>PO<sub>4</sub> [pH 7.8], 1mM ATP, and 1mM dithiothreitol) and 50 µL of 1mM d-luciferin potassium salt 138 139 (Prolume). The neutralization half-maximal inhibitory dilution ( $ID_{50}$ ) represents the plasma 140 dilution to inhibit 50% of the infection of 293T-ACE2 cells by pseudoviruses.

#### 141 **Statistical analysis**

142 Symbols represent biologically independent samples from individuals. Statistics were 143 analyzed using GraphPad Prism version 8.0.1 (GraphPad, San Diego, CA). Each dataset was 144 tested for statistical normality and this information was used to apply the appropriate 145 (parametric or nonparametric) statistical test. p values < 0.05 were considered significant; significance values are indicated as \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, \*\*\*P<0.0001, ns, non-146 147 significant.

148

#### 149 **Results**

150 We first monitored the capacity of plasma to recognize the D614G and BQ.1.1 Spikes 151 after the third and fourth doses of mRNA vaccine by flow cytometry (Figure 1B-D). For the 152 D614G S, no significant differences were observed four weeks and four months after the 153 third dose of vaccine between individuals with or without recent BTI. In contrast, four weeks 154 after the fourth dose of mRNA vaccine, individuals with recent BTI recognized better the 155 D614G S than donors with no recent BTI regardless of the vaccine type received (Figure 1B). 156 For the BQ.1.1 S, at the M4-Va3 timepoint donors with recent BTI better recognized the S 157 than individuals with no recent infection, and this difference in recognition was more

7 of 19

158 significant four weeks after the fourth dose (Figure 1C). The level of BQ.1.1 S recognition 159 was significantly lower compared to D614G S in donors without recent BTI (Figure 1D), in 160 agreement with recent reports [4,5]. In donors who had recently been infected, there was a 161 significant but smaller difference in the level of recognition between the two Spikes 162 compared to the other group.

163

164 We also measured the neutralizing activity of plasma against the D614G and BQ.1.1 S (Figure 1E-G). We observed pattern similar to that measured for Spike recognition. No 165 166 significant differences were observed between the two groups at W4-Va3 and M4-Va3 167 timepoints (Figure 1E-F). In contrast, four weeks after the fourth dose, donors with recent 168 BTI had a significantly higher level of neutralizing activity against D614G and BQ.1.1 S. All 169 donors with recent BTI who received a fourth dose developed neutralizing antibodies against 170 BQ.1.1 S, while some donors who just received four doses of vaccine were still not able to 171 neutralize this Spike. As observed for S recognition (Figure 1D), BQ.1.1 Spike was 172 significantly less neutralized than D614G S, even after four doses of mRNA vaccine (Figure 173 1G). However, the difference in neutralization between the two S was smaller in the group 174 with recent BTI.

175

176 The Moderna BA.1 bivalent vaccine (blue points) tended to induce better recognition and 177 neutralization than the other vaccine platforms including the Pfizer BA.4/5 bivalent vaccine 178 with lesser decrease of recognition and neutralization of BQ.1.1 S (Figure 1B-G, Figure S2). 179 These differences did not reach statistical significance; whether this is due to the relatively 180 low number of samples tested remains to be determined.

181

182

### 183 **Discussion**

184 Since its emergence in late 2021, the Omicron variant continues to evolve into new 185 subvariants that are increasingly resistant to monoclonal antibodies and vaccination [5,26– 186 30]. To address vaccine resistance, bivalent mRNA vaccines, expressing both the original

187 Spike and one of the parental lineages of Omicron (BA.1 or BA.4/5) Spike, have been 188 developed and are now being administered in several jurisdictions worldwide. However, 189 although the bivalent mRNA vaccine has been shown to increase the level of protection 190 against BA.5 variant in mice [31], evidence of its superior effectiveness in the human 191 population remains to be demonstrated, especially against sub-lineages with newly acquired 192 immune escape mutations. Recent studies showed that both monovalent and bivalent 193 vaccines induced low humoral responses against BQ.1.1, but recent breakthrough infection 194 before vaccination strongly improved these responses [32]. The results presented herein 195 support these observations.

196 As previously reported in numerous studies, including ours, hybrid immunity led to 197 better humoral responses against the BQ.1.1 and other recent variants than just vaccination 198 [4,5,32]. Also, we observed that after 4 doses of mRNA vaccine and no recent BTI, some 199 donors did not have neutralizing activity against pseudoviral particles bearing the BQ.1.1 200 Spike. Whether these changes of recognition and neutralization translate into greater risk of 201 severe disease is currently unknown. In contrast, BTI likely increased the breadth of 202 neutralizing antibodies since all donors had detectable levels of neutralization against 203 BQ.1.1.

204

205 These results indicate that further efforts have to be devoted to improve vaccines against 206 new SARS-CoV-2 variants of concern. Whether immune responses comparable to those 207 observed with breakthrough infections could be obtained with new vaccine formulations 208 remains to be determined.

209

210 Author Contributions: A.T., R.B. and A.F. conceived the study. A.T., M.B., H.M., J.P., 211 G.G-L., R.B. and A.F. performed, analyzed, and interpreted the experiments. A.T. performed 212 statistical analysis. H.M., G.G-L., M.C., and A.F. contributed unique reagents. L.G., P.A., 213 C.M., C.T., D.E.K., Y.G. and V.M.-L. collected and provided clinical samples. R.B., G.D.S., 214 and I.L. provided scientific input related to VOCs and vaccine efficacy. A.T. and A.F. wrote 215 the manuscript with inputs from others. Every author has read, edited and approved the final 216 manuscript.

9 of 19

217 Funding: This work was supported by le Ministère de l'Economie et de l'Innovation du 218 Québec, Programme de soutien aux organismes de recherche et d'innovation to A.F. and by 219 the Fondation du CHUM. This work was also supported by a CIHR foundation grant 220 #352417, by a CIHR operating Pandemic and Health Emergencies Research grant #177958, 221 by an Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI) 222 #41027 to A.F. The PlasCov biobank was supported by funding from the COVID-19 223 Immunity Task Force (CITF) which is supported by the Public Health Agency of Canada 224 (PHAC). Work on variants presented was also supported by the Sentinelle COVID Quebec 225 network led by the LSPQ in collaboration with Fonds de Recherche du Québec Santé (FRQS) 226 to A.F. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 227 950-232424. C.T. is the Pfizer/Université de Montréal Chair on HIV translational research. 228 V.M.-L is supported by a FRQS Junior 2 salary award. A.T. was supported by MITACS 229 Accélération postdoctoral fellowship. M.B. was the recipient of a CIHR master's scholarship 230 award. The funders had no role in study design, data collection and analysis, decision to 231 publish, or preparation of the manuscript. We declare no competing interests.

232

233 Institutional Review Board Statement: The study was conducted in accordance with the 234 Declaration of Helsinki in terms of informed consent and approval by an appropriate 235 institutional board. The protocol was approved by the Ethics Committee of CHUM (19.381, 236 approved on February 28, 2022) and Héma-Québec (2022-016, approved on October 7, 2022). 237

238

239 Informed Consent Statement: Informed consent was obtained from all subjects involved in 240 the study.

241

242 **Data Availability Statement:** Further information, data reported in this paper, and requests 243 for resources and reagents should be directed to and will be fulfilled by the lead contact, 244 Andrés Finzi (andres.finzi@umontreal.ca) upon request.

- 246 Acknowledgments: The authors are grateful to the donors who participated in this study.
- 247 The authors thank the CRCHUM BSL3 and Flow Cytometry Platforms for technical
- assistance.
- 249
- 250 **Conflicts of Interest:** The authors declare no conflict of interest.

#### 251 References

- 252 1. Données sur les variants du SRAS-CoV-2 au Québec Available online: 253 https://www.inspq.qc.ca/covid-19/donnees/variants (accessed on 6 December 2022).
- 254 2. CDC COVID Data Tracker Weekly Review Available online: 255 https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html (accessed on 256 6 December 2022).
- 257 3. Qu, P.; Evans, J.P.; Faraone, J.; Zheng, Y.-M.; Carlin, C.; Anghelina, M.; Stevens, P.;
- 258 Fernandez, S.; Jones, D.; Lozanski, G.; et al. Enhanced Neutralization Resistance of SARS-
- 259 CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. Cell Host & 260 *Microbe* **2022**, doi:10.1016/j.chom.2022.11.012.
- 261 4. Tauzin, A.; Nicolas, A.; Ding, S.; Benlarbi, M.; Medjahed, H.; Chatterjee, D.; Dionne,
- 262 K.; Gong, S.Y.; Gendron-Lepage, G.; Bo, Y.; et al. SARS-CoV-2 Omicron Subvariants Spike
- 263 Recognition and Neutralization Elicited after the Third Dose of MRNA Vaccine 2022, 264 2022.08.03.22278386.
- 265 5. Kurhade, C.; Zou, J.; Xia, H.; Liu, M.; Chang, H.C.; Ren, P.; Xie, X.; Shi, P.-Y. Low
- 266 Neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by Parental MRNA
- 267 Vaccine or a BA.5-Bivalent Booster. Nat Med 2022, 1-1, doi:10.1038/s41591-022-02162-x.
- 268 FDA Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech 6.
- 269 Bivalent COVID-19 Vaccines for Use as a Booster Dose, Https://Www.Fda.Gov/News-
- 270 Events/Press-Announcements/Coronavirus-Covid-19-Update-Fda-Authorizes-Moderna-
- 271 Pfizer-Biontech-Bivalent-Covid-19-Vaccines-Use Available online:
- 272 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-
- 273 authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use (accessed on 6 274 December 2022).
- 275 7. EMA First Adapted COVID-19 Booster Vaccines Recommended for Approval in the
- 276 Https://Www.Ema.Europa.Eu/En/News/First-Adapted-Covid-19-Booster-Vaccines-EU.
- 277 Recommended-Approval-Eu Available online: https://www.ema.europa.eu/en/news/first-
- 278 adapted-covid-19-booster-vaccines-recommended-approval-eu (accessed on 6 December 279 2022).
  - 280 8. Health Canada Health Canada Authorizes COVID-19 Vaccine Booster Targeting the 281 Subvariants, Omicron **BA.4/BA.5** Https://Www.Canada.ca/En/Health-
  - 282 Canada/News/2022/10/Health-Canada-Authorizes-Covid-19-Vaccine-Booster-Targeting-
  - 283 the-Omicron-Ba4ba5-Subvariants.Html Available online: https://www.canada.ca/en/health-
  - 284 canada/news/2022/10/health-canada-authorizes-covid-19-vaccine-booster-targeting-the-
  - 285 omicron-ba4ba5-subvariants.html (accessed on 6 December 2022).
  - 286 9. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron Available 287 **BA.4/BA.5** Adapted Bivalent Vaccine Pfizer online:
  - 288 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-
  - 289 complete-submission-european-medicines (accessed on 6 December 2022).
  - **SPIKEVAX**<sup>TM</sup> 290 10. Canada Information online: Available 291 https://www.modernacovid19global.com/ca/ (accessed on 6 December 2022).

11. Ntziora, F.; Kostaki, E.G.; Karapanou, A.; Mylona, M.; Tseti, I.; Sipsas, N.V.; 292 293 Paraskevis, D.; Sfikakis, P.P. Protection of Vaccination versus Hybrid Immunity against

- 294 Infection with COVID-19 Omicron Variants among Health-Care Workers. Vaccine 2022, 40,
- 295 7195-7200, doi:10.1016/j.vaccine.2022.09.042.
- 296 12. Altarawneh, H.N.; Chemaitelly, H.; Ayoub, H.H.; Tang, P.; Hasan, M.R.; Yassine, H.M.;
- 297 Al-Khatib, H.A.; Smatti, M.K.; Coyle, P.; Al-Kanaani, Z.; et al. Effects of Previous Infection
- 298 and Vaccination on Symptomatic Omicron Infections. N Engl J Med 2022, 387, 21-34,
- 299 doi:10.1056/NEJMoa2203965.
- 300 13. Carazo, S.; Skowronski, D.M.; Brisson, M.; Barkati, S.; Sauvageau, C.; Brousseau, N.;
- 301 Gilca, R.; Fafard, J.; Talbot, D.; Ouakki, M.; et al. Protection against Omicron (B.1.1.529)
- 302 BA.2 Reinfection Conferred by Primary Omicron BA.1 or Pre-Omicron SARS-CoV-2
- 303 Infection among Health-Care Workers with and without MRNA Vaccination: A Test-
- 304 Negative Case-Control Study. The Lancet Infectious Diseases 2022, 0, doi:10.1016/S1473-
- 305 3099(22)00578-3.
- 306 14. Tauzin, A.; Nayrac, M.; Benlarbi, M.; Gong, S.Y.; Gasser, R.; Beaudoin-Bussières, G.;
- 307 Brassard, N.; Laumaea, A.; Vézina, D.; Prévost, J.; et al. A Single Dose of the SARS-CoV-
- 308 2 Vaccine BNT162b2 Elicits Fc-Mediated Antibody Effector Functions and T Cell
- 309 Responses. Cell Host & Microbe 2021, 0, doi:10.1016/j.chom.2021.06.001.
- 310 15. Tauzin, A.; Gong, S.Y.; Beaudoin-Bussières, G.; Vézina, D.; Gasser, R.; Nault, L.;
- 311 Marchitto, L.; Benlarbi, M.; Chatterjee, D.; Nayrac, M.; et al. Strong Humoral Immune 312
- Responses against SARS-CoV-2 Spike after BNT162b2 MRNA Vaccination with a 16-Week Microbe 313 Interval between Doses. Cell Host & 2022, 30. 97-109.e5,
- 314 doi:10.1016/j.chom.2021.12.004.
- 315 16. Stamatatos, L.; Czartoski, J.; Wan, Y.-H.; Homad, L.J.; Rubin, V.; Glantz, H.; Neradilek,
- M.; Seydoux, E.; Jennewein, M.F.; MacCamy, A.J.; et al. MRNA Vaccination Boosts Cross-316
- 317 Variant Neutralizing Antibodies Elicited by SARS-CoV-2 Infection. Science 2021,
- 318 eabg9175, doi:10.1126/science.abg9175.
- 17. Tauzin, A.; Gong, S.Y.; Chatterjee, D.; Ding, S.; Painter, M.M.; Goel, R.R.; Beaudoin-319
- 320 Bussières, G.; Marchitto, L.; Boutin, M.; Laumaea, A.; et al. A Boost with SARS-CoV-2
- 321 BNT162b2 MRNA Vaccine Elicits Strong Humoral Responses Independently of the Interval
- 322 between the First Two Doses. Cell Reports 2022, 41, doi:10.1016/j.celrep.2022.111554.
- 323 18. Bazin, R.; Rochette, S.; Perreault, J.; Fournier, M.-J.; Grégoire, Y.; Boivin, A.; Lewin,
- 324 A.; Germain, M.; Renaud, C. Development and Use of a Method Based on the Anti-N
- 325 Reactivity of Longitudinal Samples to Better Estimate SARS-CoV-2 Seroprevalence in a
- 326 Vaccinated Population 2022, 2022.08.15.22278798.
- 327 19. Germain, M.; Lewin, A.; Bazin, R.; Dieudé, M.; Perreault, J.; Boivin, A.; Grégoire, Y.;
- 328 Renaud, C. Cohort Profile: A Québec-Based Plasma Donor Biobank to Study COVID-19
- Immunity (PlasCoV) 2022, 2022.11.09.22282156. 329
- 330 20. Prévost, J.; Richard, J.; Gasser, R.; Ding, S.; Fage, C.; Anand, S.P.; Adam, D.; Vergara,
- 331 N.G.; Tauzin, A.; Benlarbi, M.; et al. Impact of Temperature on the Affinity of SARS-CoV-
- Glycoprotein 332 for ACE2. 2021. 2 Spike Host J Biol Chem 101151. 333 doi:10.1016/j.jbc.2021.101151.

- 21. Jennewein, M.F.; MacCamy, A.J.; Akins, N.R.; Feng, J.; Homad, L.J.; Hurlburt, N.K.; 334
- 335 Seydoux, E.; Wan, Y.-H.; Stuart, A.B.; Edara, V.V.; et al. Isolation and Characterization of
- 336 Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. Cell Rep 2021, 36,
- 337 109353, doi:10.1016/j.celrep.2021.109353.
- 22. Gong, S.Y.; Chatterjee, D.; Richard, J.; Prévost, J.; Tauzin, A.; Gasser, R.; Bo, Y.; 338
- 339 Vézina, D.; Goyette, G.; Gendron-Lepage, G.; et al. Contribution of Single Mutations to
- 340 Selected SARS-CoV-2 Emerging Variants Spike Antigenicity. Virology 2021, 563, 134–145,
- 341 doi:10.1016/j.virol.2021.09.001.
- 342 23. Chatterjee, D.; Tauzin, A.; Marchitto, L.; Gong, S.Y.; Boutin, M.; Bourassa, C.;
- 343 Beaudoin-Bussières, G.; Bo, Y.; Ding, S.; Laumaea, A.; et al. SARS-CoV-2 Omicron Spike 344
- Recognition by Plasma from Individuals Receiving BNT162b2 MRNA Vaccination with a 345 16-Week Interval between Doses. Cell Rep 2022, 110429, doi:10.1016/j.celrep.2022.110429.
- 346 24. Prévost, J.; Gasser, R.; Beaudoin-Bussières, G.; Richard, J.; Duerr, R.; Laumaea, A.;
- 347 Anand, S.P.; Govette, G.; Benlarbi, M.; Ding, S.; et al. Cross-Sectional Evaluation of
- 348 Humoral Responses against SARS-CoV-2 Spike. Cell Rep Med 2020, 1, 100126,
- 349 doi:10.1016/j.xcrm.2020.100126.
- 25. Perreault, J.; Tremblay, T.; Fournier, M.-J.; Drouin, M.; Beaudoin-Bussières, G.; 350
- 351 Prévost, J.; Lewin, A.; Bégin, P.; Finzi, A.; Bazin, R. Waning of SARS-CoV-2 RBD 352 Antibodies in Longitudinal Convalescent Plasma Samples within 4 Months after Symptom 353 Onset. Blood 2020, 136, 2588–2591, doi:10.1182/blood.2020008367.
- 354 26. Qu, P.; Faraone, J.; Evans, J.P.; Zou, X.; Zheng, Y.-M.; Carlin, C.; Bednash, J.S.;
- Lozanski, G.; Mallampalli, R.K.; Saif, L.J.; et al. Neutralization of the SARS-CoV-2 355 356 Omicron BA.4/5 and BA.2.12.1 Subvariants. New England Journal of Medicine 2022, 386,
- 357 2526-2528, doi:10.1056/NEJMc2206725.
- 27. Tuekprakhon, A.; Nutalai, R.; Dijokaite-Guraliuc, A.; Zhou, D.; Ginn, H.M.; Selvaraj, 358
- 359 M.; Liu, C.; Mentzer, A.J.; Supasa, P.; Duyvesteyn, H.M.E.; et al. Antibody Escape of SARS-
- 360 CoV-2 Omicron BA.4 and BA.5 from Vaccine and BA.1 Serum. Cell 2022, 185, 2422-
- 361 2433.e13, doi:10.1016/j.cell.2022.06.005.
- 362 28. Wang, Q.; Guo, Y.; Iketani, S.; Nair, M.S.; Li, Z.; Mohri, H.; Wang, M.; Yu, J.; Bowen,
- A.D.; Chang, J.Y.; et al. Antibody Evasion by SARS-CoV-2 Omicron Subvariants 363
- 364 BA.2.12.1, BA.4, & BA.5. Nature 2022, 1–3, doi:10.1038/s41586-022-05053-w.
- 365 29. Sheward, D.J.; Kim, C.; Fischbach, J.; Sato, K.; Muschiol, S.; Ehling, R.A.; Björkström,
- 366 N.K.; Hedestam, G.B.K.; Reddy, S.T.; Albert, J.; et al. Omicron Sublineage BA.2.75.2
- 367 Exhibits Extensive Escape from Neutralising Antibodies. The Lancet Infectious Diseases 368 2022, 0, doi:10.1016/S1473-3099(22)00663-6.
- 369 30. Arora, P.; Kempf, A.; Nehlmeier, I.; Schulz, S.R.; Jäck, H.-M.; Pöhlmann, S.; Hoffmann,
- 370 M. Omicron Sublineage BQ.1.1 Resistance to Monoclonal Antibodies. The Lancet Infectious
- Diseases 2022, 0, doi:10.1016/S1473-3099(22)00733-2. 371
- 372 31. Scheaffer, S.M.; Lee, D.; Whitener, B.; Ying, B.; Wu, K.; Liang, C.-Y.; Jani, H.; Martin,
- 373 P.; Amato, N.J.; Avena, L.E.; et al. Bivalent SARS-CoV-2 MRNA Vaccines Increase
- 374 Breadth of Neutralization and Protect against the BA.5 Omicron Variant in Mice. Nat Med
- 375 **2022**, 1–11, doi:10.1038/s41591-022-02092-8.

14 of 19


- 376 32. Hoffmann, M.; Behrens, G.M.N.; Arora, P.; Kempf, A.; Nehlmeier, I.; Cossmann, A.;
- 377 Manthey, L.; Dopfer-Jablonka, A.; Pöhlmann, S. Effect of Hybrid Immunity and Bivalent
- 378 Booster Vaccination on Omicron Sublineage Neutralisation. The Lancet Infectious Diseases
- 379 **2022**, *0*, doi:10.1016/S1473-3099(22)00792-7.
- 380
- 381

1 able 1. Characteristics of the SAKS-Cov-2 vaccinated conort				
		Entire cohort	No recent BTI	Recent BTI
Number		63	43	20
Age**		59 (24-84)	63 (31-84)	54 (24-67)
Sex	Female (n)	38	27	11
	Male (n)	25	16	9
Days between the third and fourth doses****		186 (101-313)	155 (101-271)	268 (134-313)
Fourth dose	Pfizer monovalent	28	22	6
	Moderna monovalent	21	18	3
	Pfizer BA.4/5	4	1	3
	Moderna BA.1	10	2	8
Days between the third and W4-Va3		26 (17-45)	25 (17-45)	28 (18-41)
Days between the third and M4-Va3		120 (90-194)	120 (90-194)	122 (92-150)
Days between the fourth and W4-Va4		28 (18-96)	28 (18-96)	25 (20-42)

#### 382 Table 1. Characteristics of the SARS-CoV-2 vaccinated cohort

383 Values displayed are medians, with ranges in parentheses. Continuous variables between 384 individuals with no recent and recent BTI were compared by using Mann-Whitney tests. p< 385 0.05 was considered statistically significant for all analyses. Statistical differences between 386 the two groups were found for the age of the donors and the interval between the third and fourth doses of vaccine. (\*\* P < 0.01; \*\*\*\* P < 0.0001). 387


<sup>16</sup> of 19



389 Figure 1. Recognition and neutralization of the D614G and BQ.1.1 Spikes after the third 390 and fourth doses of SARS-CoV-2 vaccine in individuals with or without a recent 391 breakthrough infection. (A) SARS-CoV-2 vaccine cohort design. The yellow box identifies 392 the three timepoints under study shown in panels B, C, E and F and the red box the period 393 presented in panels D and G. (B-D) 293T cells were transfected with the full-length D614G 394 or BQ.1.1 S, stained with the CV3-25 mAb or with plasma from vaccinated individuals and 395 analyzed by flow cytometry. The values represent the MFI normalized by CV3-25 mAb 396 binding. (E-G) Neutralization activity was measured by incubating pseudoviruses bearing 397 SARS-CoV-2 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting 398 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution ( $ID_{50}$ ) values were 399 determined using a normalized non-linear regression using GraphPad Prism software. 400 Individuals vaccinated with Pfizer monovalent, Moderna monovalent, Pfizer bivalent


- 401 (BA.4/5) or Moderna bivalent (BA.1) fourth dose are represented by orange, green, purple
- 402 and blue points respectively. Limits of detection are plotted. Error bars indicate means  $\pm$
- SEM. (\* P < 0.05; \*\* P < 0.01; \*\*\*\* P < 0.0001; ns, non-significant). 403

18 of 19



405

406 Figure S1. Anti-N level measured after the third and fourth doses of SARS-CoV-2 407 vaccine. Anti-N level was measured in plasma from vaccinated donors by ELISA. Donors 408 are considered to have a recent BTI when a significant increase of anti-N Abs level between 409 W4-Va3 and M4-Va3 or between M4-Va3 and W4-Va4 is observed, according to a recently 410 described analytical approach based on the ratio of anti-N absorbance. Individuals with no 411 recent BTI and recent BTI are represented by gray and red dots respectively. (\* P < 0.05; 412 \*\*\*\* P < 0.0001; ns, non-significant).





415 Figure S2. Recognition and neutralization of the D614G and BQ.1.1 Spikes after the 416 fourth doses of SARS-CoV-2 vaccine in individuals with or without a recent 417 breakthrough infection. (A) 293T cells were transfected with the full-length D614G or 418 BQ.1.1 S, stained with the CV3-25 mAb or with plasma from vaccinated individuals and 419 analyzed by flow cytometry. The values represent the MFI normalized by CV3-25 mAb 420 binding. (B) Neutralization activity was measured by incubating pseudoviruses bearing 421 SARS-CoV-2 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting 422 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID<sub>50</sub>) values were 423 determined using a normalized non-linear regression using GraphPad Prism software. 424 Individuals vaccinated with Pfizer monovalent, Moderna monovalent, Pfizer bivalent 425 (BA.4/5) or Moderna bivalent (BA.1) fourth dose are represented by orange, green, purple 426 and blue points respectively. Limits of detection are plotted. Error bars indicate means  $\pm$ 427 SEM.